161 related articles for article (PubMed ID: 35717870)
21. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1.
Zhou Q; Wu W; Jia K; Qi G; Sun XS; Li P
Eur J Med Chem; 2022 Dec; 244():114830. PubMed ID: 36228414
[TBL] [Abstract][Full Text] [Related]
22. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
23. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
25. Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction.
Xiong J; Pecchi VG; Qui M; Ivanov AA; Mo X; Niu Q; Chen X; Fu H; Du Y
Assay Drug Dev Technol; 2018; 16(2):96-106. PubMed ID: 29634317
[TBL] [Abstract][Full Text] [Related]
26. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
[TBL] [Abstract][Full Text] [Related]
28. Neural crest specification and migration independently require NSD3-related lysine methyltransferase activity.
Jacques-Fricke BT; Gammill LS
Mol Biol Cell; 2014 Dec; 25(25):4174-86. PubMed ID: 25318671
[TBL] [Abstract][Full Text] [Related]
29. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
30. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.
Zhang M; Yang Y; Zhou M; Dong A; Yan X; Loppnau P; Min J; Liu Y
Biochem Biophys Res Commun; 2021 Sep; 569():199-206. PubMed ID: 34271259
[TBL] [Abstract][Full Text] [Related]
31. Discovery of the First-in-class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
bioRxiv; 2024 Feb; ():. PubMed ID: 38464025
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.
Wang XR; Wang S; Mu HX; Xu KY; Wang XT; Shi JT; Cui QH; Zhang LW; Chen SW
Eur J Med Chem; 2022 Dec; 244():114821. PubMed ID: 36242985
[TBL] [Abstract][Full Text] [Related]
34. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug.
Lee B; Kim DG; Lee A; Kim YM; Cui L; Kim S; Choi I
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):51-66. PubMed ID: 36305287
[TBL] [Abstract][Full Text] [Related]
36. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
[TBL] [Abstract][Full Text] [Related]
37. Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders.
Chen J; Zhu W; Zhang W; Tong Y; Xu F; Pang J
ACS Med Chem Lett; 2024 May; 15(5):659-666. PubMed ID: 38746900
[TBL] [Abstract][Full Text] [Related]
38. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
39. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
40. Structural insights into the C-terminus of the histone-lysine N-methyltransferase NSD3 by small-angle X-ray scattering.
Belviso BD; Shen Y; Carrozzini B; Morishita M; di Luccio E; Caliandro R
Front Mol Biosci; 2024; 11():1191246. PubMed ID: 38516186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
